Jul 27, 2021By: Rounak Jain
Almost doubled its net profit to ₹2,160 crore in the June 2021 quarter compared to ₹1,112 crore a year ago. Net interest income surged by 11 percent to ₹7,760 crore in the same period.
Nearly halved its loss to ₹4,451 crore in the June 2021 quarter from ₹8,438 crore a year ago. Revenue more than doubled to ₹66,407 crore from ₹31,983 crore, year-on-year.
Its June 2021 quarter net profit jumped by nearly 4 times to ₹1,174 crore from ₹303 crore a year ago. Revenue surged by 38 percent to ₹29,335 crore, while the order book stood at ₹3.24 lakh crore.
Dr. Reddy’s Laboratories, IndusInd Bank, InterGlobe Aviation, Torrent Pharmaceuticals, Aarti Drugs, Dixon Technologies, Canara Bank, Granules India, Godawari Power and Ispat, Mahindra Logistics, Morepen Laboratories, VST Industries, among others.
Its June 2021 quarter net profit rose sharply by over four times to ₹4,224 crore against ₹1,033 crore a year ago. Revenue surged by 78 percent to ₹28,412 crore, year-on-year.
Vedanta also announced expansion of its BALCO plant at an outlay of ₹6,611 crore, alongside a new carbon facility at an outlay of ₹635 crore in Jharsuguda, Odisha.
Its subsidiary Biocon Biologics has received an exclusive licence to manufacture and commercialise monoclonal antibody used in the treatment of COVID-19.
Reported a net profit of ₹337 crore in the June 2021 quarter as against a loss of ₹72 crore a year ago. Revenue more than doubled to ₹1,140 crore in the same period.
Announced plans to double the capacity of its Jajpur plant at an outlay of ₹2,150 crore.
Approved fundraising plan worth ₹700 crore via issue of securities.